AbbVie has collaborated with Anima Biotech for the discovery and development of mRNA biology modulators against three oncology and immunology targets.
The collaboration will leverage Anima’s mRNA Lightning platform and AbbVie’s oncology and immunology expertise to discover novel mRNA biology modulators against the targets.
AbbVie will have exclusive rights to license, develop and market the programs.
Under the terms of the agreement, Anima will receive an upfront payment of US$42 million and will also be eligible for option fees and research and development milestones of up to US$540 million.
The company will also receive additional commercial milestones and tiered royalties on net product sales.
It will also have the option to add three more destinations on the same terms as the original partnership, potentially increasing the overall value of the collaboration.
Jonathon Sedgwick, Vice President and Global Head of AbbVie Discovery Research, said, “This collaboration will provide AbbVie with access to Anima’s leading technology platform and deep expertise in mRNA biology, and will help leverage AbbVie’s world-class drug discovery and development capabilities continue to strengthen to make a difference the patient’s life.
“Small molecule modulation of mRNA biology is a novel approach and has the potential to address ‘untreatable’ targets with implications for multiple therapeutic areas.”
Anima’s mRNA Lightning platform uses automated large-scale phenotypic screening in live mRNA biology and MOAi technology to identify small molecule mRNA drugs and their mechanisms of action.
Yochi Slonim, Co-Founder and CEO of Anima, said: “Anima’s differentiated approach to small molecule mRNA drugs combines phenotypic screening with AI-driven elucidation of mechanism of action.
“The power of our mRNA Lightning platform is validated by our numerous partnerships and a growing internal pipeline.”
Cell and gene therapy coverage in Pharmaceutical Technology is powered by Cytiva.
Editorial content is independently produced and follows highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.